148 related articles for article (PubMed ID: 38292054)
1. Clinical and microbiological predictors of healing in Buruli ulcer disease.
Agbavor B; Agbanyo A; Loglo AD; Antwi PB; Ackam N; Adjei J; Frimpong V; Boampong K; Frimpong M; Addo MG; Wansbrough-Jones M; Amoako YA; Phillips RO
J Clin Tuberc Other Mycobact Dis; 2024 Feb; 34():100415. PubMed ID: 38292054
[TBL] [Abstract][Full Text] [Related]
2. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
[TBL] [Abstract][Full Text] [Related]
3. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
Phillips RO; Robert J; Abass KM; Thompson W; Sarfo FS; Wilson T; Sarpong G; Gateau T; Chauty A; Omollo R; Ochieng Otieno M; Egondi TW; Ampadu EO; Agossadou D; Marion E; Ganlonon L; Wansbrough-Jones M; Grosset J; Macdonald JM; Treadwell T; Saunderson P; Paintsil A; Lehman L; Frimpong M; Sarpong NF; Saizonou R; Tiendrebeogo A; Ohene SA; Stienstra Y; Asiedu KB; van der Werf TS;
Lancet; 2020 Apr; 395(10232):1259-1267. PubMed ID: 32171422
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load.
Frimpong M; Agbavor B; Duah MS; Loglo A; Sarpong FN; Boakye-Appiah J; Abass KM; Dongyele M; Amofa G; Tuah W; Frempong M; Amoako YA; Wansbrough-Jones M; Phillips RO
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007689. PubMed ID: 31449522
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Streptomycin-Rifampicin treatment of Buruli Ulcer in two Ghanaian districts.
Iddrisah FN; Yeboah-Manu D; Nortey PA; Nyarko KM; Anim J; Antara SN; Kenu E; Wurapa F; Afari EA
Pan Afr Med J; 2016; 25(Suppl 1):13. PubMed ID: 28149438
[TBL] [Abstract][Full Text] [Related]
7. Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana.
Amoako YA; Loglo AD; Frimpong M; Agbavor B; Abass MK; Amofa G; Ofori E; Ampadu E; Asiedu K; Stienstra Y; Wansbrough-Jones M; van der Werf T; Phillips RO
BMC Infect Dis; 2021 Apr; 21(1):331. PubMed ID: 33832460
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection.
Marion E; Chauty A; Kempf M; Le Corre Y; Delneste Y; Croue A; Marsollier L
Open Forum Infect Dis; 2016 Jan; 3(1):ofw013. PubMed ID: 26925431
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.
Andreoli A; Ruf MT; Sopoh GE; Schmid P; Pluschke G
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2809. PubMed ID: 24762629
[TBL] [Abstract][Full Text] [Related]
10. Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in
Amoako YA; Agbanyo A; Novignon J; Owusu L; Tuffour J; Asante-Poku A; Hailemichael Y; Mosweu I; Canter R; Opondo C; Allen E; Pitt C; Yeboah-Manu D; Walker SL; Marks M; Phillips RO;
NIHR Open Res; 2022; 2():59. PubMed ID: 36825217
[TBL] [Abstract][Full Text] [Related]
11. Providing insight into the incubation period of Mycobacterium ulcerans disease: two case reports.
Amoako YA; Frimpong M; Awuah DO; Plange-Rhule G; Boakye-Yiadom E; Agbavor B; Sarpong F; Ahor H; Adu E; Danso KG; Abass MK; Asiedu K; Wansbrough-Jones M; Phillips RO
J Med Case Rep; 2019 Jul; 13(1):218. PubMed ID: 31315637
[TBL] [Abstract][Full Text] [Related]
12. Phytotherapy against buruli ulcer in the Health District of Yamoussoukro (Cote d'Ivoire) : Identification, description, and symbolic functions of the plants and recipes used.
Adjet AA; Kouame D; Fokou G
Med Sante Trop; 2016 Nov; 26(4):408-413. PubMed ID: 28073729
[TBL] [Abstract][Full Text] [Related]
13. An MMP/TIMP ratio scoring system as a potential predictive marker of diabetic foot ulcer healing.
Luanraksa S; Jindatanmanusan P; Boonsiri T; Nimmanon T; Chaovanalikit T; Arnutti P
J Wound Care; 2018 Dec; 27(12):849-855. PubMed ID: 30557113
[TBL] [Abstract][Full Text] [Related]
14. Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer.
Barogui YT; Klis SA; Johnson RC; Phillips RO; van der Veer E; van Diemen C; van der Werf TS; Stienstra Y
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004594. PubMed ID: 27097163
[TBL] [Abstract][Full Text] [Related]
15. Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana.
Addison NO; Pfau S; Koka E; Aboagye SY; Kpeli G; Pluschke G; Yeboah-Manu D; Junghanss T
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005331. PubMed ID: 28245242
[TBL] [Abstract][Full Text] [Related]
16. Prolonged healing of venous leg ulcers: the role of venous reflux, ulcer characteristics and mobility.
Hjerppe A; Saarinen JP; Venermo MA; Huhtala HS; Vaalasti A
J Wound Care; 2010 Nov; 19(11):474, 476, 478 passim. PubMed ID: 21135795
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
[TBL] [Abstract][Full Text] [Related]
18. Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.
O'Brien DP; Friedman ND; McDonald A; Callan P; Hughes A; Walton A; Athan E
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006357. PubMed ID: 29554101
[TBL] [Abstract][Full Text] [Related]
19. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial.
Sheehan P; Jones P; Caselli A; Giurini JM; Veves A
Diabetes Care; 2003 Jun; 26(6):1879-82. PubMed ID: 12766127
[TBL] [Abstract][Full Text] [Related]
20. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
